Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Agios Pharmaceuticals, Inc. is not a good value stock. Agios Pharmaceuticals, Inc. is not a good growth stock. Agios Pharmaceuticals, Inc. is not very popular among insiders. Agios Pharmaceuticals, Inc. is a good stock to invest in, but there are better stocks to choose.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and devel...

News

Zacks Research Comments on Agios Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:AGIO)

Ticker Report Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities researchers at Zacks Research decreased their Q1 2025 earnings estimates for Agios Pharmaceuticals in a report released on Monday...\n more…

Q1 2025 EPS Estimates for Agios Pharmaceuticals, Inc. Lowered by Zacks Research (NASDAQ:AGIO)

Zolmax Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Analysts at Zacks Research lowered their Q1 2025 earnings estimates for Agios Pharmaceuticals in a report released on Monday, September...\n more…

Agios Pharmaceuticals announces FDA granted ODD to AG-946

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Agios Pharmaceuticals' treatment of myelodysplastic syndromes gets orphan status

Candriam S.C.A. Acquires Shares of 322,882 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Ticker Report Candriam S.C.A. acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...\n more…

Candriam S.C.A. Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Zolmax Candriam S.C.A. bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and...\n more…